Marta Epeldegui
Overview
Explore the profile of Marta Epeldegui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Shieh A, Epeldegui M, Karlamangla A, Greendale G
JCI Insight
. 2019 Dec;
5(2).
PMID: 31830000
BACKGROUNDInflammation is implicated in many aging-related disorders. In animal models, menopause leads to increased gut permeability and inflammation. Our primary objective was to determine if gut permeability increases during the...
22.
Epeldegui M, Conti D, Guo Y, Cozen W, Penichet M, Martinez-Maza O
Sci Rep
. 2019 Jun;
9(1):9371.
PMID: 31253857
The risk for non-Hodgkin lymphoma (NHL) is markedly increased in persons living with human immunodeficiency virus (HIV) infection, and remains elevated in those on anti-retroviral therapy (cART). Both the loss...
23.
Epeldegui M, Magpantay L, Guo Y, Halec G, Cumberland W, Yen P, et al.
AIDS
. 2018 Feb;
32(7):945-954.
PMID: 29424776
Background: Chronic immune activation is a harbinger of AIDS-associated non-Hodgkin lymphoma (AIDS-NHL), yet the underlying basis is unclear. Microbial translocation, the passage of microbial components from the gastrointestinal tract into...
24.
Serieys L, Lea A, Epeldegui M, Armenta T, Moriarty J, VandeWoude S, et al.
Proc Biol Sci
. 2018 Jan;
285(1871).
PMID: 29343604
Understanding how human activities influence immune response to environmental stressors can support biodiversity conservation across increasingly urbanizing landscapes. We studied a bobcat () population in urban southern California that experienced...
25.
Epeldegui M, Martinez-Maza O
For Immunopathol Dis Therap
. 2017 Jul;
6(1-2):79-90.
PMID: 28702272
HIV infection is associated with a greatly elevated risk for the development of non-Hodgkin lymphoma (NHL), which while diminished, remains elevated in the highly active antiretroviral therapy (HAART) era. Chronic...
26.
Epeldegui M, Lee J, Martinez A, Widney D, Magpantay L, Regidor D, et al.
Clin Cancer Res
. 2015 Sep;
22(2):328-36.
PMID: 26384320
Purpose: The aims of this study were to determine whether pretreatment plasma levels of cytokines and immune activation-associated molecules changed following treatment for AIDS-NHL with rituximab plus infusional EPOCH, and...
27.
Epeldegui M, Blom B, Uittenbogaart C
Eur J Immunol
. 2014 Nov;
45(3):728-37.
PMID: 25408362
In contrast to peripheral plasmacytoid DCs (pDCs), thymic pDCs constitutively express low levels of IFN-α. This leads to induction of interferon secondary genes (ISGs) in medullary thymocytes, raising the question...
28.
Guo Y, Siewe B, Epeldegui M, Detels R, Landay A, Martinez-Maza O
J Acquir Immune Defic Syndr
. 2013 Jun;
64(2):204-10.
PMID: 23722608
Background: AIDS-related non-Hodgkin lymphoma (AIDS-NHL) is a common AIDS-defining cancer. Prior studies suggest that chronic B-cell activation precedes AIDS-NHL diagnosis. Activation of B cells by multiple factors, including Toll-like receptor...
29.
Colantonio A, Epeldegui M, Jesiak M, Jachimowski L, Blom B, Uittenbogaart C
PLoS One
. 2011 Sep;
6(8):e24252.
PMID: 21904619
Type I interferons have been typically studied for their effects in the context of bacterial or viral infections. However in this report, we provide evidence that Interferon-alpha (IFN-α) expressing cells...
30.
Epeldegui M, Vendrame E, Martinez-Maza O
Immunol Res
. 2010 Aug;
48(1-3):72-83.
PMID: 20717742
HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL). The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss...